Investigational drug · Phase 3
BCD-131
Also called: pegdarbepoetin beta
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BCD-131"
First trial start
2025
Mar 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BCD-131", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anemia
- Chronic Kidney Disease
- Chronic Kidney Disease Patients on Hemodialysis
- Chronic Kidney Disease 5D
Approved drugs for the same conditions: Anemia · Chronic kidney disease · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "BCD-131" as an intervention, largest first.
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisPivotal-lookingActive, not recruiting
BiocadIndustry
NCT07119372 · 228 participants (planned) · Start Mar 1, 2025 · Primary completion May 12, 2026
Drug: BCD-131 (pegdarbepoetin beta); Mircera (methoxypolyethylene glycol-epoetin beta) · For: Anemia; Chronic Kidney Disease; Chronic Kidney Disease Patients on Hemodialysis and 1 more
Sites: Krasnodar, Russia; Novosibirsk, Russia; Orenburg, Russia · 14 sites in all
BiocadIndustry
NCT03519243 · 75 participants · Start Oct 24, 2017 · Primary completion Dec 1, 2018
Drug: BCD-131; Mircera · For: Anemia
Sites: Minsk, Belarus; Saint Petersburg, Russia · 3 sites in all
BiocadIndustry
NCT02731469 · 45 participants · Start Jun 15, 2016 · Primary completion Mar 2017
Drug: BCD-131; Mircera® and 1 more · For: Reticulocyte Count
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- OfirnoflastHT-6184Phase 22 trials
Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome
- SAL-0951SAL-0951 groupPhase 21 trial
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.